We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New RT-LAMP Assay Offers Affordable and Reliable Pathogen Detection for Resource-Limited Settings

By LabMedica International staff writers
Posted on 15 Jul 2025

The high cost and logistical complexities associated with rapid, point-of-care tests have long hampered widespread access to molecular diagnostics, especially in low- and middle-income countries. More...

In these settings, the need for accurate and affordable pathogen detection is particularly pressing, especially during outbreaks. Traditional diagnostic methods often rely on expensive tests, require cold chains for transport and storage, and demand sophisticated laboratory setups, making them difficult to deploy in resource-limited environments. Researchers have now developed a new, more affordable solution aimed at addressing these issues, making molecular diagnostics more accessible and feasible in underserved areas.

A team from the Vienna BioCenter (Vienna, Austria) and the West African Center for Cell Biology of Infectious Pathogens (WACCBIP) at the University of Ghana (Accra, Ghana) has developed a lyophilized open-source reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for pathogen detection. This assay uses non-proprietary enzymes, including reverse transcriptase, DNA polymerase, and uracil DNA glycosylase, to reduce reliance on expensive commercial solutions. The assay is both heat-stable and robust, making it possible to store and transport the diagnostic tools at ambient or elevated temperatures, bypassing the need for cold chains. The RT-LAMP assay is adaptable for rapid detection of various pathogens and can be used with swab or gargle samples, demonstrating high sensitivity and providing a colorimetric result. The open-source nature of the assay means that the enzyme mixture can be self-produced, further driving down costs and improving accessibility.

The assay was tested in a proof-of-concept study with lyophilized RT-LAMP reaction mixes shipped to Ghana, where it showed performance comparable to results obtained in Vienna. This study, published in Life Science Alliance, demonstrated that the assay is both robust and suitable for field implementation across diverse settings. The researchers envision multiple models for implementation, ranging from centralized production to decentralized in-lab preparation. The team is working to make the assay more widely accessible, having deposited essential vectors and providing protocols for protein expression and purification on publicly accessible platforms. Moving forward, the researchers plan to further validate the system's performance across a broader range of pathogens and settings.

“By making reliable pathogen detection both affordable and independent of complex logistics like cold chains, our protocols empower laboratories and public health institutions worldwide to take control of their diagnostic capabilities, especially during outbreaks,” said co-first author Martin Matl, PhD.

Related Links:
Vienna BioCenter
WACCBIP


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
POCT RT-qPCR Analyzer
BG-X6
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.